NEWS

June 21, 2021

Jean-Frederic Colombel, MD: The Commitment to Biologics for IBD

It can be a long, painstaking process to develop new drugs for any disease.

However, the progress made in inflammatory bowel disease (IBD) treatments due to the advent of biologics has been impressive for many in the industry.

In an interview with HCPLive®, Jean-Frederic Colombel, MD, Director Inflammatory Bowel Disease Center Icahn School of Medicine at Mount Sinai, explained the added value biologics have given to IBD treatments and why there still remains some gaps in treatment for this patient population.

Read More…